Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of seven years, starting in February 2025. Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological combination therapy combining two active...
Society for Regenerative Medicine, scheduled to be held at Pacifico Yokohama in Yokohama, Japan from March 20 to March 22, 2025. The companies will showcase their research findings through poster presentations, focusing on the ongoing development...
common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open today, Wednesday, March 19, 2025. The CUSIP number for the Company's common stock will remain the same. With a legacy spanning over 25 years, this strategic...
Pharma West Africa is Nigeria’s leading pharmaceutical trade exhibition and will host 200+ exhibiting companies and 3,000+ trade visitors. The exhibition will connect the key buyers and decision makers from the regions pharmaceutical industry with...
outcomes of patients with r/r AML receiving Actimab-A + CLAG-M to CLAG-M alone. The trial is expected to be initiated in 2025. Sandesh Seth, Actinium's Chairman and CEO, said, "There is significant momentum for Actimab-A with the publication of...
Vilcek Foundation Prizes for Creative Promise in Biomedical Science are being accepted now through June 9, 2025. These $50,000 prizes are given each year to three early- to mid-career immigrant scientists living in the United States who have made...
therapy, and completion of this study moves us closer to making that goal a reality." About metastatic prostate cancer: In 2025 it is estimated that there will be 50,055 new cases of metastatic prostate cancer in the United States (de novo...
3 trial in psoriatic arthritis." UCB's data for BIMZELX in moderate-to-severe PSO will be presented as six posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, U.S., March 7–11.1-6 These abstracts complement...
pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug...
announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette’s manufacturing, global supply chain, and operational strategy, ensuring efficiency, and...
clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing, completed February 3, 2025. “As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale...
properties. We will continue exploring its therapeutic potential to benefit patients worldwide." On January 10, 2025, Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech") entered into a global licensing agreement...
or placebo. The first participant was dosed on July 1, 2024, and primary completion is expected in the second half of 2025. “HB-500 is designed to induce robust and durable immunity and is a key component of a combination strategy for a potential...
rates of delivering new potential therapeutics.” Customers can place orders for workstations and assay kits starting mid-2025. Applications will include broad workflows across protein sample preparation, molecular, cell, and other biochemical and...
dose-limiting acneiform rash. The company expects to report top-line results from this trial during the first half of 2025 at a major medical meeting. "Based on the broad use of EGFRi's to treat cancer and the dermal toxicity that often emerges,...
dose Phase 1 clinical trials studying STM-01 in patients with heart failure are expected to begin in the first quarter of 2025. STM-21: STM-21 is a secretome-based therapeutic comprised of the bioactive molecules secreted by nCPCs, such as...
myeloma in China. Ouro holds exclusive rights outside of Greater China and intends to start its first Phase 1 study in 2025. Examples of B cell mediated diseases include systemic lupus erythematosus, scleroderma, rheumatoid arthritis, Sjögren's,...
to evaluate safety, pharmacokinetics, and efficacy in patients. The trial is expected to initiate in the first half of 2025 and will be conducted by Mediar. Following completion of the Phase 2 study, Lilly will have the right to lead all further...
College of Pharmacy and Health Sciences with interactive health care events and programs beginning in the Fall semester of 2025 and encourage pharmacy students to pursue cosmetic science careers. Pharmacy students and members of the Cosmetic...
agreement dated December 4, 2024, with the approval of certain items in NLS's extraordinary general meeting on January 7, 2025. As previously detailed in NLS's Report on Form 6-K submitted to the Securities and Exchange Commission on December 4,...
